Press Releases

Bridge Medicines Appoints William J. Polvino, M.D., As Chief Executive Officer

New York, NY – March 27, 2017

Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the appointment of William J. Polvino, M.D., as Chief Executive Officer (CEO). In conjunction, Kathleen Metters, Ph.D., who served as the interim CEO upon the establishment of Bridge Medicines in October 2016, will continue to have an operating role within Bridge Medicines, and will Chair the Scientific Advisory Board.


Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). Tri-I TDI, also a collaborative venture of the three research institutions and Takeda, is working on approximately 50 early-stage drug discovery projects spanning therapeutic areas that include infectious disease, oncology, neuropsychiatry and rare diseases. As CEO of Bridge Medicines, Dr. Polvino will be responsible for building a portfolio of early-stage drug discovery projects and advancing each program from animal proof of principle to clinical trials by providing expert clinical, operational and managerial expertise.


Carl S. Goldfischer, managing director of Bay City Capital and executive chairman of Bridge Medicines, remarked, “As an entrepreneur and executive of exceptional skill, Bill is ideally equipped to lead Bridge Medicines as the company embarks on its mission. We look forward to benefiting from Bill’s expertise as Bridge Medicines seeks to harness the combined strengths of academic discovery and industrial know-how to change the paradigm of drug development and help to transform New York into one of the world’s leading biotechnology hubs.”


Dr. Polvino commented, “Bridge Medicines is in an honored position to work with some of the world’s most renowned scientists and institutions. It is a privilege to take their groundbreaking work forward for the benefit of patients. As CEO, I will work closely with our esteemed partners to ensure the company succeeds in its mission of accelerating the transition of promising projects into the clinic.”


Dr. Polvino is a pharmaceutical entrepreneur with more than 26 years of experience in the pharmaceutical and healthcare arena. Most recently, Dr. Polvino was president and chief executive officer of Veloxis Pharmaceuticals A/S (NASDAQ: VELO), a public biotechnology company that deploys proprietary formulation technology to develop and commercialize innovative oral drug products. Prior to Veloxis, Dr. Polvino held positions at Helsinn Therapeutics (formerly Sapphire Therapeutics), where he also served as the company’s president and CEO. During his tenure at Helsinn, he advanced novel in-licensed, preclinical stage, new chemical entities into late-stage clinical development and registration in the supportive oncology space. Dr. Polvino has also held executive and senior-level positions in drug development at Merck, Wyeth and Theravance.


Dr. Polvino earned a medical degree from Rutgers Medical School and a B.S. in Biology from Boston College. He was also a fellow in clinical pharmacology at the National Institutes of Health and trained in internal medicine at Massachusetts General Hospital.

About Bridge Medicines

Bridge Medicines is a pioneering drug-discovery company focused on advancing promising early technologies in major academic institutions from human proof-of-concept to clinical development. Launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management and Bay City Capital, Bridge Medicines is a groundbreaking initiative that provides an unbroken, fully funded and professionally staffed path from discovery to drug candidate.


Karen Heidelberger
Deerfield Management
(212 692-7140

Carl S. Goldfischer, MD
Bay City Capital, LLC
(415) 835-9385

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept

The Tri-Institutional Therapeutics Discovery Institute, a partnership between Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda, joins with Deerfield Management and Bay City Capital to create an accelerated path to innovative therapies to treat disease

NEW YORK and OSAKA, JAPAN (Oct. 31, 2016)

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

Bridge Medicines builds upon the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute, known as Tri-I TDI. Scientists at the Tri-I TDI, which launched in 2013, are working in the laboratory on approximately 50 early-stage drug discovery projects — spanning therapeutic areas including infectious disease, oncology, neuropsychiatry and rare diseases — with the hope that they might be translated into future treatments for patients.

Research projects accepted into the Tri-I TDI will now be able to graduate to Bridge Medicines, where they will be given financial, operational and managerial support to move seamlessly from a validating, proof-of-concept study to an in-human clinical trial. Typically, investigators behind promising early-stage discoveries must search for a biopharmaceutical company to purchase or license their intellectual property, or find a funding opportunity to support additional research. This process can be time consuming and may shift investigators’ focus away from science, slowing down and in some cases ending the development path.


The launch of Bridge Medicines is a truly exciting development in New York’s biotechnology space, said Dr. Michael Foley, Sanders Director of the Tri-I TDI. We’re tapping into the distinguished talent at Sloan Kettering, Rockefeller and Weill Cornell Medicine and offering entrepreneurs access to support what’s next in biopharmaceuticals. Bridge Medicines will enable us to advance promising projects farther down the development pipeline, providing new therapies to patients as quickly as possible.


Memorial Sloan Kettering has always had an unwavering commitment to the discovery and development of novel cancer drugs, said Craig B. Thompson, president and CEO of Memorial Sloan Kettering. Bridge Medicines will provide an innovative and unique opportunity to continue that commitment, with the goal of delivering the best drugs to patients in the shortest amount of time.


This unique academic-industry partnership advances the remarkable work of the Tri-I TDI, further extending the ability of basic scientists such as those at our three institutions to explore the full potential of their discoveries for the benefit of patients, said Dr. Richard P. Lifton, president of The Rockefeller University. We are thrilled to be a part of this initiative.


Bridge Medicines is a transformative concept for therapeutics development that will provide enormous hope to patients and incredibly exciting opportunities for researchers to take their discoveries into the clinic, said Weill Cornell Medicine Interim Dean Augustine M.K. Choi. Weill Cornell Medicine is honored to be part of this groundbreaking investment in medicine.


As we looked ahead and beyond the current research climate, we knew this flagship collaboration would continue to push the boundaries of what’s possible in medical research. The establishment of Bridge Medicines is that next phase, said Dr. Andrew Plump, chief medical and scientific officer of Takeda Pharmaceutical Company. Takeda is thrilled to be a partner in this innovative approach to further research and drug discovery for the benefit of more patients around the world.


To be part of this project, working alongside Takeda, Deerfield and three of the world’s leading research and clinical institutions in helping to advance translation research and build the New York City-based biotechnology infrastructure is a great honor, said Carl S. Goldfischer, managing director of Bay City Capital.


Harnessing the combined strengths of academic discovery, industrial know-how, capital and entrepreneurship, Bridge Medicines is a breakthrough in the translation of ideas into treatments, said William Slattery, a partner at Deerfield. As Bridge Medicines changes the paradigm of drug development, it can also help transform New York into a world-class center of biotechnology excellence. We at Deerfield look forward to collaborating with Takeda, our illustrious academic partners at The Rockefeller University, Memorial Sloan Kettering and Weill Cornell, and Bay City Capital in our mission to advance healthcare.

The Investment Model

In current drug-development models, intellectual property is often sold or licensed to a pharmaceutical company when it is still a basic compound or antibody. This early stage is fraught with risk; companies may choose to discontinue a project if it doesn’t meet expectations during the clinical trial process – or the project may not find funding at all. The Tri-I TDI program reflects a different paradigm: Principal investigators collaborate with medicinal chemists from Takeda to demonstrate the therapeutic viability of new compounds through preclinical proof-of-concept studies.


Any project successfully graduating from Tri-I TDI is eligible to enter Bridge Medicines, where it can continue along the drug development pipeline without interruption and be professionally managed in a venture capital setting. This includes projects meant to develop drugs to combat diseases such as tuberculosis, which strikes large numbers of people in underdeveloped countries but few people in the Western world, and Niemann-Pick type C, which is rare and has a small potential market.


Because Bridge Medicines projects are funded as a group, even some riskier – but potentially transformational – ideas can obtain financial support. The arrangement could shave a decade off of the typical process to go from a promising discovery to medical use.


Bridge Medicines makes this essential portion of the drug development pathway possible with the backing of its investing partners, who assist in the creation of the business and scientific development plans. Projects that are part of the Bridge Medicines portfolio would be supported through filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration. Once that hurdle is passed, Bridge Medicines would work with the participating scientists to establish and fund biopharmaceutical companies responsible for managing individual projects and advancing them to clinical trials, with the intention of basing the new companies in New York City. These entities would be able to raise additional funds to support research on related targets, or engage with another biopharmaceutical company to complete the development process.


“Bridge Medicines’ mission is to increase the odds of successfully developing novel therapeutics to meet the needs of patients while simultaneously helping to build a vibrant biotechnology sector in New York City,” Dr. Foley said.


Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medicine were advised by WilmerHale. The investors were represented by Paul Hastings.

Media Contacts


Memorial Sloan Kettering
Cancer Center

Caitlin Hool



The Rockefeller

Katherine Fenz



Weill Cornell

Jennifer Gundersen